2026-10-14T23:23:58Z https://www.scidb.cn/oai

10.57760/sciencedb.32107 2026-04-09T14:14:38Z

2026-04-09 Clinical data-IgA Nephropathy doi:10.57760/sciencedb.32107 en Immunoglobulin A nephropathy (IgA nephropathy, IgAN) is the most common primary glomerular disease worldwide. Currently, the optimized immunosuppressive regimens for patients at moderate to high risk still need to be explored. Telitacicept is a recombinant TACI-Fc fusion protein that can simultaneously neutralize BLyS/BAFF and APRIL, inhibiting B cell differentiation into plasma cells that produce pathogenic Gd-IgA1. This study aims to compare the short-term efficacy of the Telitacicept combined with glucocorticoid/immunosuppressant regimen versus the traditional immunosuppressant regimen (using glucocorticoid/immunosuppressant alone) in the treatment of IgAN in the real world. Telitacicept; Combination therapy; Proteinuria; Retrospective study; IgA Nephropathy Xin-yue Wu Cha-han Suolinge Han-wen Liao Jing Li Chen Lu PUBLIC https://opendatacommons.org/licenses/by/1-0/ dataset Science Data Bank